MDLN at a glance
Medline Inc (MDLN, SEC CIK 2046386) filed its latest 10-K annual report on February 25, 2026, a 10-Q quarterly report on August 5, 2026, an 8-K current report on August 5, 2026 and Form 4 insider filings as recently as October 6, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- For the fiscal year ended December 31, 2025 (FY2025), Medline Inc (MDLN) reported revenue of $28.4 billion (up 11.5% from FY2024) and net income of $1.2 billion. Diluted EPS was -$0.01.
- As of June 30, 2026, 35 institutional investment managers tracked by SignalX reported holding Medline Inc (MDLN) shares worth $15.4 billion in 13F-HR filings.
- The most recent insider open-market sale reported on Form 4 was by GIC Private Ltd on October 6, 2026 of 7,183,013 shares at $35.05 per share.
- In the last 90 days, MDLN insiders reported 0 open-market purchases ($0) and 11 open-market sales ($879.9M) on Form 4, a net sale of $879.9M.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Revenue · FY2025
- $28.4B
- +11.5% vs prior year
- Insiders · 90 days
- 0 buys · 11 sells
- Net −$879.9M
- 13F holders
- 35 funds
- $15.4B · +3 vs prior quarter
- Latest 10-Q
- Aug 5, 2026
- Quarterly report
SignalX for MDLN
Don't miss the next MDLN filing
- Alerts as it files. A push when MDLN files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut MDLN, by share count.
- Ask anything. An AI agent that reads every MDLN filing and answers with sources.
MDLN alerts on your phone. Follow it in the SignalX Android app.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| GIC Private Ltd | Sell | Oct 6, 2026 | 7,183,013 | $35.05 |
| GIC Private Ltd | Sell | Oct 6, 2026 | 2,088,987 | $35.05 |
| GIC Private Ltd | Sell | Oct 5, 2026 | 1,688,690 | $35.78 |
| GIC Private Ltd | Sell | Oct 2, 2026 | 7,146,941 | $34.33 |
| GIC Private Ltd | Sell | Oct 2, 2026 | 2,570,999 | $35.35 |
| Miller Stephen L | A | Aug 19, 2026 | 87,667 | - |
| Boyle James M | A | Aug 19, 2026 | 764,252 | - |
| GIC Private Ltd | Sell | Aug 14, 2026 | 100,000 | $35.80 |
Financial SummaryXBRL
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Profitability | |||
| Revenue | $23.2B | $25.5B | $28.4B |
| Gross Profit | - | $7.0B | $7.5B |
| Operating Income | $1.3B | $2.1B | $2.2B |
| Net Income | - | $1.2B | $1.2B |
| Gross Margin | - | 27.3% | 26.4% |
| Op. Margin | 5.4% | 8.4% | 7.8% |
| Net Margin | - | 4.6% | 4.1% |
| Balance Sheet | |||
| Total Assets | - | $36.0B | $38.5B |
| Equity | - | - | $10.7B |
| ROE | - | - | 10.8% |
| Per Share | |||
| EPS | - | - | $-0.01 |
| Cash Flow | |||
| Operating CF | $1.7B | $1.8B | $1.7B |
| CapEx | $275.0M | $354.0M | $447.0M |
Source: XBRL data in Medline Inc (MDLN)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
13F Fund Holdings: Quarterly Trend
Latest: Q2 2026Aggregate MDLN share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q2 2026 | 35 | $15.38B |
| Q1 2026 | 32 | $15.26B |
| Q4 2025 | 25 | $13.40B |
- Invesco Ltd+17.38M (+83%)
- FMR LLC (Fidelity)+10.41M (+28%)
- BlackRock+9.47M (+56%)
- Morgan Stanley+5.90M (+38%)
- State Street Corp+3.62M (+75%)
- Viking Global Investors−6.59M (-58%)
- Citadel Advisors LLC−1.56M (-98%)
- Two Sigma Investments−944.0K (-83%)
- Millennium Management−889.8K (-45%)
- JPMorgan Chase & Co−852.2K (-58%)
- Allstate+64.7K
- Bridgewater Associates LP+19.8K
- AQR Capital Management+10.7K
- M&T Bank+7.9K
- Renaissance Technologies LLC−143.7K
Source: 13F-HR filings on SEC EDGAR (aggregated from 92 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
MDLN filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
8-K current reports
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
Related Health Care companies
- ARAY · ACCURAY INCSurgical & Medical Instruments & Apparatus
- ATEC · Alphatec Holdings, Inc.Surgical & Medical Instruments & Apparatus
- ANGO · ANGIODYNAMICS INCSurgical & Medical Instruments & Apparatus
- ANIK · Anika Therapeutics, Inc.Surgical & Medical Instruments & Apparatus
- AORT · ARTIVION, INC.Surgical & Medical Instruments & Apparatus
- ATRC · AtriCure, Inc.Surgical & Medical Instruments & Apparatus
- RCEL · AVITA Medical, Inc.Surgical & Medical Instruments & Apparatus
- BAX · Baxter InternationalSurgical & Medical Instruments & Apparatus
MDLN SEC filings: frequently asked questions
Are MDLN insiders buying or selling?
In the last 90 days, Medline Inc (MDLN) officers, directors and 10% owners reported no open-market purchases and 11 open-market sales worth $879.9 million by 1 insider on Form 4. Many insider sales are pre-planned or for taxes, so purchases usually carry more information.
Which institutions hold MDLN stock?
As of June 30, 2026, the largest Medline Inc (MDLN) holders among the 13F filers tracked by SignalX were Carlyle Group ($7.4 billion), FMR LLC (Fidelity) ($1.9 billion), Invesco Ltd ($1.5 billion), BlackRock ($1.0 billion), Morgan Stanley ($852.1 million). 13F-HR reports are filed up to 45 days after each quarter ends.
What was MDLN's revenue in fiscal year 2025?
For the fiscal year ended December 31, 2025 (FY2025), Medline Inc (MDLN) reported revenue of $28.4 billion (up 11.5% from FY2024) and net income of $1.2 billion. Diluted EPS was -$0.01. The figures come from the XBRL data in the 10-K.
What are the latest MDLN SEC filings?
Medline Inc (MDLN) filed its latest 10-K annual report on February 25, 2026, a 10-Q quarterly report on August 5, 2026, an 8-K current report on August 5, 2026 and a Form 4 insider filing on October 6, 2026.
What is MDLN's SEC CIK number?
Medline Inc (MDLN)'s SEC Central Index Key (CIK) is 2046386. EDGAR lists every MDLN filing under that number.
Ask anything about MDLN
The research agent reads MDLN's filings, financials, insider trades and 13F holders, then answers with sources.